This infographic and the studies discussed were funded by AstraZeneca. This content is intended for US Healthcare Professionals only.
Can the perioperative approach in resectable G/GEJ adenocarcinoma be improved? Surgery and perioperative FLOT are the primary treatment approach in locally advanced disease, but recurrence is common. MATTERHORN, a global Phase III trial, evaluated perioperative durvalumab plus FLOT vs placebo plus FLOT. This infographic reviews the trial design, survival outcomes, key subgroups, and surgical data.
You will learn:
- MATTERHORN Phase III trial design
- Survival outcomes and key subgroups
- Surgical outcomes and safety profile
